- Home
- IDYA vs HUT Comparison
IDYA vs HUT Comparison
Compare IDYA & HUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- HUT
- Stock Information
- Founded
- IDYA 2015
- HUT 2011
- Country
- IDYA United States
- HUT United States
- Employees
- IDYA N/A
- HUT N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- HUT Finance: Consumer Services
- Sector
- IDYA Health Care
- HUT Finance
- Exchange
- IDYA Nasdaq
- HUT Nasdaq
- Market Cap
- IDYA 2.3B
- HUT 2.7B
- IPO Year
- IDYA 2019
- HUT N/A
- Fundamental
- Price
- IDYA $24.44
- HUT $37.79
- Analyst Decision
- IDYA Buy
- HUT Strong Buy
- Analyst Count
- IDYA 14
- HUT 14
- Target Price
- IDYA $47.75
- HUT $31.21
- AVG Volume (30 Days)
- IDYA 1.2M
- HUT 5.7M
- Earning Date
- IDYA 11-03-2025
- HUT 11-12-2025
- Dividend Yield
- IDYA N/A
- HUT N/A
- EPS Growth
- IDYA N/A
- HUT N/A
- EPS
- IDYA N/A
- HUT 1.48
- Revenue
- IDYA $7,000,000.00
- HUT $138,543,000.00
- Revenue This Year
- IDYA $62.30
- HUT $74.79
- Revenue Next Year
- IDYA $285.58
- HUT $116.78
- P/E Ratio
- IDYA N/A
- HUT $25.78
- Revenue Growth
- IDYA N/A
- HUT N/A
- 52 Week Low
- IDYA $13.45
- HUT $10.04
- 52 Week High
- IDYA $37.19
- HUT $38.31
- Technical
- Relative Strength Index (RSI)
- IDYA 49.04
- HUT 83.05
- Support Level
- IDYA $24.24
- HUT $24.20
- Resistance Level
- IDYA $25.49
- HUT $28.66
- Average True Range (ATR)
- IDYA 1.35
- HUT 2.08
- MACD
- IDYA -0.15
- HUT 0.95
- Stochastic Oscillator
- IDYA 27.13
- HUT 96.04
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About HUT Hut 8 Corp.
Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.